Intragastric balloon has role in comprehensive weight-loss program
Intragastric balloon systems provide a minimally invasive weight-loss option for patients with a BMI of 30 to 40 — typically underserved population. At Mayo Clinic, the Orbera balloon is part of a unique multidisciplinary weight-loss program.

Exomic sequencing cheaper, faster, but yields still low
Sequencing protein-coding genes is increasingly less expensive and time-consuming, but the yield of clinically useful information remains small.

Trial to evaluate novel agent for HE
A large multicenter trial aims to study the benefit of ornithine phenylacetate for patients hospitalized with severe hepatic encephalopathy (HE).

Current therapies for fistulizing Crohn's disease (CD) often fail to achieve complete or sustained fistula closure. A phase I study evaluates the safety of autologous stromal cell transfer using a biomatrix for the treatment of CD-associated perianal fistulae.

See all Gastroenterology and Hepatology Clinical Trials at Mayo Clinic

Oct. 23-24, 2015, in Scottsdale, Ariz.
Offered in conjunction with TGEN and Honor Health, this conference provides a multidisciplinary overview of the molecular biology of pancreatic cancer and the importance of early diagnosis and treatment.

Dec. 4-5, 2015, in Phoenix
This course explores advances in high-resolution manometry and impedance monitoring, discusses new techniques in endoscopic detection and treatment of Barrett's esophagus, and offers insights into relatively new diseases such as eosinophilic esophagitis.

Gastrointestinal Advances in Endoscopy and Minimally Invasive Surgery: Where Are We in 2016?
April 8-10, 2016, in Jacksonville, Fla.
This course covers recent advances in minimally invasive and therapeutic endoscopy approaches to gastrointestinal diseases. It includes expert lectures, live case demonstrations from the OR and endoscopy suite, as well as video cases.

See all Gastroenterology Continuous Professional Development courses

Individualizing Diagnosis and Therapy for IBS
Mayo researchers were the first to report that a defined genetic mutation caused a subset of irritable bowel syndrome (IBS). This Grand Rounds presentation discusses a mutation of the SCN5A gene that affects the Nav1.5 sodium channel in the gastrointestinal smooth muscle and pacemaker cells.

Visit the Medical Professional Video Center to view specialty and Grand Rounds presentations

• Phoenix/Scottsdale, Arizona
  866-629-6362 (toll-free)
• Jacksonville, Florida
  800-634-1417 (toll-free)
• Rochester, Minnesota
  800-533-1564 (toll-free)
• Online Referrals

• Career Opportunities
• Clinical Trials at Mayo Clinic
• Mayo School of Continuous Professional Development